Empagliflozin for better right heart function in pulmonary hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with group 1 pulmonary arterial hypertension (PAH) by a doctor.
- You have reduced right heart function, measured by an echo or other tests.
- You are 18 years or older and able to read and write in English.
- You are already on a stable PAH treatment for at least 8 weeks (or 24 weeks for certain drugs).
- You are not currently taking certain diabetes drugs (SGLT2 inhibitors) or insulin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial is testing two heart medications, empagliflozin and ranolazine, to see if they can improve right heart function in people with pulmonary hypertension and right ventricular failure. Participants will monitor their symptoms using a smartphone or tablet.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.